Safety and Efficacy of Topically Applied Selected Cutibacterium acnes Strains over Five Weeks in Patients with Acne Vulgaris: An Open-label, Pilot Study.
|Title||Safety and Efficacy of Topically Applied Selected Cutibacterium acnes Strains over Five Weeks in Patients with Acne Vulgaris: An Open-label, Pilot Study.|
|Publication Type||Journal Article|
|Year of Publication||2019|
|Authors||Karoglan, A, Paetzold, B, de Lima, JPereira, Brüggemann, H, Tüting, T, Schanze, D, Güell, M, Gollnick, H|
|Journal||Acta Derm Venereol|
|Date Published||2019 Dec 01|
|Keywords||Acne Vulgaris, Administration, Topical, Adolescent, Benzoyl Peroxide, Female, Humans, Male, Microbiota, Patient Safety, Pilot Projects, Prognosis, Propionibacteriaceae, Propionibacterium acnes, Skin, Time Factors, Transformation, Bacterial, Treatment Outcome, Young Adult|
Imbalance in skin microflora, particularly related to certain Cutibacterium acnes strains, may trigger acne. Application of non-acne-causing strains to the skin may modulate the skin microbiome and thereby lead to a reduction in acne. This pilot study evaluates the safety and efficacy of microbiome modulation on acne-prone skin. The study had 2 phases: active induction (5% benzoyl peroxide gel, 7 days) and interventional C. acnes strains treatment (5 weeks). Patients were randomized to either topical skin formulations PT1 (2 strains of C. acnes Single Locus Sequence Typing [SLST] type C3 and K8, 50% each) or PT2 (4 strains of C. acnes SLST type C3 [55%], K8 [5%], A5 [30%] and F4 [10%]). Safety and efficacy was evaluated in 14 patients (PT1=8/14, PT2=6/14). Skin microbiome composition shifted towards study formulations. No untoward adverse events, visible irritation, or significant flare-up were observed. Non-inflamed lesions and skin pH were reduced. Comedone counts improved clinically with no deterioration in inflammatory lesions.
|Alternate Journal||Acta Derm Venereol|